Stage IIIC Cutaneous Melanoma AJCC v7 Recruiting Phase 2 Trials for Talimogene laherparepvec (DB13896)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02965716Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTreatment